Detalhe da pesquisa
1.
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Haematologica
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497158
2.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36632738
3.
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
Br J Haematol
; 192(6): 1011-1014, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32410259
4.
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Br J Haematol
; 193(2): 280-289, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476434
5.
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Hematol Oncol
; 38(3): 257-265, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32356913
6.
Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study.
Ann Hematol
; 99(2): 283-291, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31872361
7.
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.
Haematologica
; 104(11): 2241-2248, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31666344
8.
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Br J Haematol
; 183(5): 755-765, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30407629
9.
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia.
Hematol Oncol
; 41(3): 567-570, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36190298
10.
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Lancet Oncol
; 18(8): 1076-1088, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28668386
11.
Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.
Br J Haematol
; 178(4): 588-591, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485042
12.
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.
Blood
; 126(8): 950-6, 2015 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26089397
13.
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Am J Hematol
; 97(5): E176-E180, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35170793
14.
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
Acta Haematol
; 137(1): 7-14, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27820922
15.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet Oncol
; 17(3): 319-331, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899778
16.
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Br J Haematol
; 172(6): 879-88, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26763986
17.
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
Haematologica
; 100(4): 517-24, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25596266
18.
The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).
Am J Hematol
; 90(6): 499-503, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25720750
19.
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.
Haematologica
; 99(3): 489-96, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24270404
20.
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.
Haematologica
; 104(1): e25-e28, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29954940